Currently, the FDA has approved certain drugs for the treatment of HR+/HER2-breast cancer, including the PI3K inhibitor alpelisib (Piqray) and the mTOR inhibitor everolimus (Afinitor) (du Rusquec et al., 2020; Alves and Ditzel, 2023). This evidence concerns the gene ERBB2 and breast cancer.